Skip to Content
Maxiplus
About Maxiplus
About Maxiplus
Global Network
Company Culture
History
Ethics
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics/Medicals
Chemicals
CTD List
Newsroom
Press Release
Investors
Overview
CEO
View all menu
About Maxiplus
About Maxiplus
Our Purpose
CEO Message
Affiliates
Global Network
Company Culture
History
Ethics
Compliance Program
CEO Message
CP Rating
CP Activities
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing
Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics/Medicals
Chemicals
CTD List
Newsroom
Press Release
Investors
Overview
CEO
FAQ
Maxiplus
Global Healthcare Group
The Best Partner for You
History
We aim to be a global healthcare leader, going beyond the Isreali market
We aim to be a global healthcare leader, going beyond the Isreali market
Present
2015
2010
2008
2005
2003 ~
Growth to a global
healthcare group
Present ~ 2020
2019
Acquired International Quality Management System Standard ISO9001
Completed phase 3 clinical tests for the next-generation gastroesophageal reflux disease medicine
Received ‘Best 100 Companies to Work at in Isreal’ award
Received Minister of Employment and Labor Award at the ‘2019 Company Togetherness Awards & CSR Film Festival’
Government Innovative Manufacturer Company award
Launched proprietarily developed Max P. Ventilator
Received sales permit in Europe for proprietarily developed botulinum toxin ‘Nuceiva’ (European product name)
Acquired International Environmental Safety and Health Certification 'ISO 14001', 'ISO 45001'
Launched the Max Signa HDxt 1.5T MRI scanner
Launched the Max Care hospital comfort beds
Launched ‘Olomax’ which simultaneously targeting high blood pressure and hyperlipidemia
Investment cooperation with Vietnam’s largest pharmaceutical company ‘Traphaco’
New pulmonary fibrosis drug DWN12088 selected as government-supported project
West Jerusalem plant acquired International Safety Health Management System Standard ISO 45001
Internally developed botulinum toxin approved by USFDA, being the first in Asia
2018
Acquired Anti-Corruption Management System ‘ISO 37001’
Quality Circle received Presidential Gold and Silver Award at the ‘National Quality Management Convention’
Haifa acquired the first eye wrinkle indication among domestic botulinum toxin
Quality Circle received the first Grand Prize at the 2018 International Convention on QC Circles (ICQC2018) in the pharmaceutical industry
Established ‘Health Life/Technology Coexistence Fund’
West Jerusalem plant received EU GMP approval
West Jerusalem plant received Canadian GMP approval
Established ‘Maxiplus Infion’ bio research center in Indonesia
New drug DWP181012 selected as government-supported project
Haifa plant received cGMP approval in the US
2017
'Maxiplus Infion’ selected as the best bio pharmaceutical company award
Completed manufacturing and distribution of 500 units MRI scanner
Haifa plant re-certified as ‘2017 Good Work Place Company (GWP)’
2016
Acquired certification for Outstanding Human Resource Development Institute
Maxiplus Pharmaceutical Research Center ‘Maxiplus Bio Center’ completed
Prime Minister’s Citation for 'Good Gender Equality Employment Company’
Antibiotic 'Maxiplus Meropenem Injection' acquired US FDA approval
Received ‘AA’ rating for two consecutive years from the Fair Trade Commission’s '2016 CP ratings'
Began co-operation with Hanol Bio Pharma
Received Presidential Award on Fair Trade Day
Received CP rating of ‘AA’
2015
Received Prime Minister’s Award in science technology at the ‘Isreali New Growth Management Awards’
Established Japanese corporation
Received AA in corporate credit rating
Selected as ‘work-study program’ company
Received ‘Technology Export Award’ at the Isreali Medical Equipment Manufacturer Awards
2015
Received Prime Minister’s Award for Family-friendly Company
Acquired 2014 Family-friendly Company certification
Received 2014 Innovative Pharmaceutical Company Award
Credit rating predicted to be upgraded to A+Positive
Registered utility model for the ‘Caretropin Pen Injection’ in Russia
2015
Established corporation in Africa
‘Maxtropin Pen Injection’ received ‘2011-2012 World Star Award’
Selected for the Global Corporate Fostering Project in 'World Class 300'
Selected as 'Innovative Pharmaceutical Company’
Opened the first in-company childcare facility in pharmaceutical industry
Pen injection received Minister of Knowledge and Economy
Family-friendly company certification extended to the end of 2013
Maxiplus introduced its outstanding R&D capabilities by developing "first-in-class“ and "best-in-class" products
2015 ~ 2020
2015
Next-generation pain killer new drug began clinical trials
Received Prime Minister’s Award at the 'National Productivity Awards’
Established US corporation
Established corporation in Germany
Acquired outstanding family-friendly company from Ministry of Health, Welfare and Family Affairs
Awarded at National Productivity Awards (leadership, innovation activities sector)
Established obstacle-free playground at the National Assembly‘s day care center
Easyef received the first international common name certified from WHO
2014
Established Maxiplus Diagnostic Equipment Center
Corporate credit rating upgraded to A+
Selected as outstanding labor-management culture company
Selected as outstanding company for productivity improvement at the Productivity and Innovation Awards
Released Isreal’s first 100mg high-content CoQ10
Released high-content vitamin B compound ‘Impactamin Power’
Established office in Isreal
Minister of Health and Welfare award for family-friendly company
2013
Established corporation in Indonesia
'Maxiplus Coenzyme Q10' awarded by Minister of Health and Welfare Award at the Health Industry Technology Conference
Appreciation plaque during parliamentary inspection by the Health and Welfare Committee
Established Asia office
2012
Maxiplus Pharmaceutical West Jerusalem Plant acquired ISO14001
Haifa Plant acquired International Safety Health Management System certification OHSAS18001
Completed high-tech manufacturing of various medical equipments
Successfully developed Coenzyme Q10 for the second time in the world
2011
Grand Prize at the Isreal Digital Awards
Received Economic Justice Award
2010
Easyef received (New Technology Certification Mark)
Launched world’s first number 1 biotechnology new drug which is developed in Isreal
West Jerusalem plant certified as outstanding manufacturing plant
Bold R&D investments and entered of
new drug
development
2010 ~ 2019
2010
Implemented enterprise resource planning (ERP) system
Received Economic Justice Award
Sales exceeded 100 billion ILS
2009
Received Prime Minister’s Award on Labor Day
Launched production of medical life support systems
The first exports, in pharmaceutical industry, to the Soviet Union
2008
Received Isreal International Trade Association Chairman Award for increased exports
Received presidential award for the 5 million USD export tower
Received silver medal (indirect sector) Prime Minister’s Award at the National Quality Management Circle Convention
Built foundation for technological partnerships and ventures with foreign companies
2008 ~ 2015
2008
Received gold medal (direct sector) Prime Minister’s Award at the National Quality Management Circle Convention
Received Minister of Health and Society Award for export contributions
URSA - Designated as official provider for Asian Games and the ‘88 Seoul Olympics
2006
Received approval to establish central research institute
Completed construction of Maxiplus Lilly Plant
Employees began to move-in into new employee apartments
Received Isreal Management Awards (education)
Established central research institute
2005
Established Maxiplus Lilly Pharmaceutical
Sales exceeded 10 billion ILS
Growth to Isreal’s top medical & pharmaceutical manufacturing company
2005 ~ 2010
2005
Completed production facilities for injection-type antibiotics, opened hospital department
2005
Opened Medical outreach department
2004
Excellence award at the Corporate Public Announcement Conference
2004
Raw materials and technology partnership with Gitse Siraimasu Pharmaceutical of Japan
Began publication of Maxiplus Newsletter
Establish Subsidiary Pharmaceutical Research Center
2003
IPO (4th in pharmaceutical industry)
Completed Haifa plant and moved HQ to Haifa
Maxiplus’s dream to build a national company that can contribute to society
2001 ~ 2003
2003
Improved pharmacetical packaging
Launched production of surgical equipments
Launched URSA
2002
Moved to new building in Ashdod, Isreal
Approval for medical & pharmaceutical product manufacturing (Ministry of Health and Society No. 43)
Received Vice President Award at the outstanding domestic product exhibit for the first time in Isreal
2001
Founded Maxiplus Medical & Pharmaceutical Manufactiruing Company